company background image
PHVS logo

Pharvaris NasdaqGS:PHVS Stock Report

Last Price

US$16.60

Market Cap

US$904.6m

7D

3.8%

1Y

-12.4%

Updated

01 Jun, 2025

Data

Company Financials +

Pharvaris N.V.

NasdaqGS:PHVS Stock Report

Market Cap: US$904.6m

PHVS Stock Overview

A late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. More details

PHVS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 61.41% per year

Risk Analysis

Makes less than USD$1m in revenue (€0)

Currently unprofitable and not forecast to become profitable over the next 3 years


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Pharvaris N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pharvaris
Historical stock prices
Current Share PriceUS$16.60
52 Week HighUS$25.50
52 Week LowUS$11.51
Beta-2.85
1 Month Change-9.64%
3 Month Change8.36%
1 Year Change-12.45%
3 Year Change-11.32%
5 Year Changen/a
Change since IPO-42.76%

Recent News & Updates

We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely

Pharvaris: Despite 30% Decline, Still Fair At Best

Dec 29

Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Dec 02
Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Recent updates

We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely

Pharvaris: Despite 30% Decline, Still Fair At Best

Dec 29

Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

Dec 02
Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Aug 16
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris: Digging Deep For Sufficient Market Size

Jan 17

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Oct 09
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

May 13
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

Jan 11
Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Sep 26
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris GAAP EPS of -€0.38

Sep 12

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Aug 22

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Jun 08
We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Dec 21
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Aug 25
We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Shareholder Returns

PHVSUS PharmaceuticalsUS Market
7D3.8%2.3%1.7%
1Y-12.4%-9.5%11.6%

Return vs Industry: PHVS underperformed the US Pharmaceuticals industry which returned -9.5% over the past year.

Return vs Market: PHVS underperformed the US Market which returned 11.6% over the past year.

Price Volatility

Is PHVS's price volatile compared to industry and market?
PHVS volatility
PHVS Average Weekly Movement8.9%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement7.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market4.1%

Stable Share Price: PHVS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: PHVS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015119Berndt Axel Modigpharvaris.com

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Pharvaris N.V. Fundamentals Summary

How do Pharvaris's earnings and revenue compare to its market cap?
PHVS fundamental statistics
Market capUS$904.59m
Earnings (TTM)-US$173.19m
Revenue (TTM)n/a
0.0x
P/S Ratio
-5.2x
P/E Ratio

Is PHVS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHVS income statement (TTM)
Revenue€0
Cost of Revenue€0
Gross Profit€0
Other Expenses€152.54m
Earnings-€152.54m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.80
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PHVS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/01 19:59
End of Day Share Price 2025/05/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharvaris N.V. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Alexandru CogutBryan Garnier & Co
Steven SeedhouseCantor Fitzgerald & Co.